New Indication Application for Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First-Line Treatment for PD-L1-Negative Non-Squamous NSCLC Accepted for Review by NMPA

China’s NMPA accepted Kelun-Biotech’s application for sac-TMT plus pembrolizumab as first-line treatment for PD-L1-negative, EGFR-negative and ALK-negative non-squamous NSCLC, making it the ADC’s seventh indication application accepted for review. In Phase III OptiTROP-Lung06, the combination showed a statistically significant and clinically meaningful PFS improvement versus pembrolizumab plus pemetrexed and platinum-based chemotherapy; OS showed a positive trend, with no new safety signals reported. The article provided no PFS effect size or review timeline.

Analysis

A strategically positive read-through for Merck & Co. (MRK), but not yet an earnings catalyst of known size. If the PFS advantage holds through review and is clinically meaningful in the detailed dataset, pairing sac-TMT with pembrolizumab could protect or extend Keytruda’s role in PD-L1-negative first-line NSCLC while shifting treatment value from chemotherapy toward an ADC. That is more favorable to Merck than a competing ADC regimen that excludes Keytruda; however, the commercial split and Merck’s incremental economics are not disclosed, and the China filing does not establish global approval or sales contribution. Kelun-Biotech captures Greater China rights; outside that territory, Merck’s partner role creates potential upside but also leaves execution and trial costs with MSD. The competitive read-through is mixed for other TROP2 programs, including AstraZeneca/Daiichi Sankyo’s datopotamab deruxtecan: a positive Phase III precedent may validate the class, but could raise the efficacy bar and intensify competition for first-line use.

Near term, acceptance for review is a modest regulatory de-risking event, not proof of approval. The key 1–3 month checks are full PFS effect size, duration of follow-up, safety/discontinuation detail, OS maturity, and Chinese review timing. Over 6–18 months, the question is whether this regimen can reproduce benefit across settings and translate into share without compromising tolerability or pricing. The contrarian point: “statistically significant and clinically meaningful” is company-reported framing; without the hazard ratio, absolute PFS gain, and mature OS, the market may overread a press release. No standalone MRK trade is justified from this filing alone.

Key Decisions for Investors

• Do not chase MRK on the filing acceptance alone. Reassess after the ESMO dataset is independently reviewed and quantify the PFS hazard ratio, absolute benefit, follow-up, and treatment discontinuations.
• Treat MRK as a watch item for franchise defense rather than a near-term earnings upgrade: verify the sac-TMT collaboration economics and whether global Phase III results support a material pembrolizumab-containing opportunity.
• Monitor Chinese CDE review and any eventual label or reimbursement terms for Kelun-Biotech; acceptance is not approval, and pricing/access could limit commercial conversion.
• Falsify the constructive thesis if the PFS advantage is small in absolute terms, OS trends weaken with follow-up, safety materially impairs treatment duration, or subsequent global studies fail to replicate efficacy.